Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus

array:24 ["pii" => "S1665268121002519" "issn" => "16652681" "doi" => "10.1016/j.aohep.2021.100552" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100552" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2021" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1665268121002507" "issn" => "16652681" "doi" => "10.1016/j.aohep.2021.100551" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100551" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Circ_0078710 promotes the development of liver cancer by upregulating TXNDC5 via miR-431-5p" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1897 "Ancho" => 3583 "Tamanyo" => 339140 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Circ_0078710 and TXNDC5 were up-regulated in liver cancer. (A, B) The expression of circ_0078710 and TXNDC5 in liver cancer tissues (n = 30) were tested by qRT-PCR. (C) Western blot assay detected the expression of TXNDC5 protein. (D) The correlation between circ_0078710 and TXNDC5 expression in liver cancer tissues was analyzed by Pearson's correlation analysis. ***P < 0.001." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Huajun Lu, Lili Gao, Jixiang Lv" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Huajun" "apellidos" => "Lu" ] 1 => array:2 [ "nombre" => "Lili" "apellidos" => "Gao" ] 2 => array:2 [ "nombre" => "Jixiang" "apellidos" => "Lv" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002507?idApp=UINPBA00004N" "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002507/v2_202205211521/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268121002556" "issn" => "16652681" "doi" => "10.1016/j.aohep.2021.100556" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100556" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3144 "Ancho" => 2917 "Tamanyo" => 550665 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Percent distribution of the common cause of cancer death, by different chronic liver disease: United States, 2018" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pegah Golabi, James M. Paik, Katherine Eberly, Leyla de Avila, Saleh A. Alqahtani, Zobair M. Younossi" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Pegah" "apellidos" => "Golabi" ] 1 => array:2 [ "nombre" => "James M." "apellidos" => "Paik" ] 2 => array:2 [ "nombre" => "Katherine" "apellidos" => "Eberly" ] 3 => array:2 [ "nombre" => "Leyla" "apellidos" => "de Avila" ] 4 => array:2 [ "nombre" => "Saleh A." "apellidos" => "Alqahtani" ] 5 => array:2 [ "nombre" => "Zobair M." "apellidos" => "Younossi" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002556?idApp=UINPBA00004N" "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002556/v2_202205211521/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Yu Zhang, Jun-Li Wu, Le-Qun Li" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Yu" "apellidos" => "Zhang" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "c" "identificador" => "aff0003" ] 2 => array:2 [ "etiqueta" => "1" "identificador" => "fn1" ] ] ] 1 => array:3 [ "nombre" => "Jun-Li" "apellidos" => "Wu" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "1" "identificador" => "fn1" ] ] ] 2 => array:4 [ "nombre" => "Le-Qun" "apellidos" => "Li" "email" => array:2 [ 0 => "zhuxun99118@163.comz" 1 => "huxun99118@163.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0002" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0001" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China" "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:3 [ "entidad" => "Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, China" "etiqueta" => "b" "identificador" => "aff0002" ] 2 => array:3 [ "entidad" => "Kaiyuan Langdong Hospital of Guangxi Medical University, Nanning, China" "etiqueta" => "c" "identificador" => "aff0003" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0001" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0002" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 956 "Ancho" => 2500 "Tamanyo" => 180364 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0002" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Overall survival rates for HCC patients with PVTT after liver resection, TACE or sorafenib in the (A) training cohort and (B) internal validation cohort." ] ] ] "textoCompleto" => "1IntroductionPortal vein tumor thrombus (PVTT) occurs in 40-60% of patients with hepatocellular carcinoma (HCC), which accounts for 80-90% of cases of primary liver cancer <a class="elsevierStyleCrossRef" href="#bib0001">[1]</a>. PVTT is a significant predictor of poor prognosis for HCC patients [<a class="elsevierStyleCrossRef" href="#bib0002">2</a>,<a class="elsevierStyleCrossRef" href="#bib0003">3</a>]. Indeed, HCC patients with PVTT survive a median of 3-4 months without intervention <a class="elsevierStyleCrossRef" href="#bib0004">[4]</a>.The optimal treatment for HCC patients with PVTT remains controversial. Currently the only officially recommended treatment is sorafenib, based on the Barcelona Clinic for Liver Cancer (BCLC) staging system <a class="elsevierStyleCrossRef" href="#bib0005">[5]</a>. However, the drug shows limited efficacy: one trial reported median survival of only 6.5 months in HCC patients with PVTT on the drug <a class="elsevierStyleCrossRef" href="#bib0006">[6]</a>. This, coupled with the drug's high price, leads many patients to refuse the treatment and opt instead for liver resection or transarterial chemoembolization (TACE). Liver resection has been associated with 1-year overall survival (OS) rates of 22-70% for HCC patients with PVTT, which may be higher than with non-surgical treatments [<a class="elsevierStyleCrossRef" href="#bib0007">7</a>,<a class="elsevierStyleCrossRef" href="#bib0008">8</a>]. TACE has also proven safe and effective for such patients [<a class="elsevierStyleCrossRef" href="#bib0003">3</a>,<a class="elsevierStyleCrossRef" href="#bib0009">9</a>]; In fact, the Hong Kong Liver Cancer system recommends TACE for patients with intrahepatic vascular invasion <a class="elsevierStyleCrossRef" href="#bib0010">[10]</a>.Combined targeted therapy had received great attention from clinicians in recent years. The combination targeted therapy may cover more molecular targets, effectively kill tumors, and weaken tumor proliferation and metastasis <a class="elsevierStyleCrossRef" href="#bib0011">[11]</a>. However, there are also some issues. First, the high price makes it unbearable for many HCC patients. Then, combined targeted therapy may be accompanied by more and more complicated complications. At last, the tumor may develop more complicated drug resistance to the combination targeted therapy <a class="elsevierStyleCrossRef" href="#bib0012">[12]</a>.In this retrospective study, we compared OS of HCC patients with PVTT following initial liver resection, TACE or sorafenib in order to identify more effective treatments. We repeated the comparison after stratifying patients by extent of portal invasion according to Cheng's PVTT classification <a class="elsevierStyleCrossRef" href="#bib0013">[13]</a>.2Material and methods2.1Study populationFrom January 2015 to December 2019, a total of 855 HCC patients with PVTT were conducted at the Affiliated Tumor Hospital of Guangxi Medical University after initial treatment with one of the following at our hospital: liver resection (LR), transarterial chemoembolization (TACE) or sorafenib.A total of 627 HCC patients with PVTT met the inclusion criteria and were randomly divided into the training cohort (n = 314) and internal validation cohort (n = 313) (<a class="elsevierStyleCrossRef" href="#fig0001">Fig. 1</a>). The method of random grouping is through“sample ()”function of R studio. The details are as follows, “Patients_data <- read.table (∼ dirict) Grouping <- function (Patients_data, m, n) {k =1 while (k<=(n-1)) {Grouping <- sample (Patients_data, m, replace = FALSE, prob = NULL) for (i in 1:m) {Patients_data <- Patients_data [-which (Patients_data == Grouping [i])]} k=k+1 Print (Grouping)} Print (Patients_data)} m: the number of patients in each group; n: the number of groups” The study was approved by the Ethics Committees of the Affiliated Tumor Hospital of Guangxi Medical University. Written informed consent was obtained from all patients for their data to be used for scientific purposes.<elsevierMultimedia ident="fig0001"></elsevierMultimedia>2.2PVTT DiagnosticsHCC patients were diagnosed with PVTT based on typical preoperative radiological feature: ultrasonography, Doppler ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and intra- or postoperative histopathology examinations. PVTT type was assigned using Cheng's classification <a class="elsevierStyleCrossRef" href="#bib0013">[13]</a>: in type I, a tumor thrombus lies in the segmental branches of the main portal vein or above; in type II, a tumor thrombus extends into the right or left portal vein; in type III, a tumor thrombus extends into the main portal vein; and in type IV, a tumor thrombus extends into the main portal vein and superior mesenteric vein. Thus, type I and II PVTT were limited to a first-order branch of the main portal vein or above (Table S1).2.3The inclusion and exclusion criteriaThe inclusion criteria: (1) they had been diagnosed with PVTT as described above; (2) they did not show macroscopic hepatic vein tumor thrombus, macroscopic bile duct tumor thrombus, extrahepatic spread, or distant metastasis; (3) they did not have any other associated malignancies; and (4) their initial treatment was liver resection, TACE or sorafenib at our hospital between January 2015 and December 2019. The exclusion criteria: (1) Patients were excluded if they had Child-Pugh class C liver function; (2) Patients had undergone palliative tumor resection; (3) Patients medical records were incomplete. The same inclusion and exclusion criteria were applied to the training and internal validation cohorts.2.4ProceduresLiver resection was offered only to patients with Child-Pugh A function or to certain patients with Child-Pugh B liver function (score ≤7). Surgical procedures were conducted as described in this paper <a class="elsevierStyleCrossRef" href="#bib0012">[12]</a>. For TACE, a microcatheter was introduced and directed into the feeding artery. An emulsion of 5-15 mL of lipiodol and 5-fluorouracil (500 mg/m2) with or without Adriamycin (30 mg/m2) was infused into the feeding artery. Tumor response to TACE was assessed one month later using computed tomography (CT) and/or MRI. TACE was repeated once every 1-2 months for a total of 2-6 cycles. HCC patients in the sorafenib group were required to receive oral sorafenib 400 mg twice daily until unacceptable toxicity or loss of clinical benefit.2.5Follow-upAfter treatment, patients were followed up every 3-4 months until death or loss to follow-up. On follow-up visits, patients were tested for alpha-fetoprotein (AFP) level, liver function, and blood tests, and they were subjected to abdominal ultrasonography, contrast-enhanced CT, and/or MRI.2.6Statistical analysesContinuous data were reported as mean ± SD or as median (interquartile range), and differences were assessed for significance using the Mann-Whitney U test. Differences in categorical data were assessed for significance using the chi-squared or Fisher's exact (2-tailed) tests. The primary endpoint was OS, which was defined from the date of surgery to the date of death or last follow-up, and analyzed using the Kaplan-Meier method. Differences in OS were assessed using the log-rank test. All statistical analyses were performed using R studio v1.2.0 (<a href="https://rstudio.com/">https://rstudio.com/</a>) and GraphPad v7.0 (<a href="https://www.graphpad.com/">https://www.graphpad.com/</a>). Differences associated with P < 0.05 were considered statistically significant.3Results3.1Characteristics of PatientsThe median age of all patients in both cohorts was 51 years, and more than 70% were male or were infected with hepatitis B virus. Approximately 3% were infected with hepatitis C virus (HCV). More than 50% patients had liver cirrhosis. All patients had compensated liver function. Most baseline clinicopathological data were similar between the training and validation cohorts. Patients in the training group showed a significantly higher age as well as better liver function (Child Pugh A) (<a class="elsevierStyleCrossRef" href="#tbl0001">Table 1</a>).<elsevierMultimedia ident="tbl0001"></elsevierMultimedia>3.2OS across all PVTT typesDuring follow-up for a median of 48 months (range, 23-71), OS rates in the training cohort were significantly longer in patients who underwent liver resection than in those who underwent TACE or sorafenib: the respective rates at 1 year were 69.0%, 56.0% and 26.4%; at 2 years, 38.4%, 23.9% and 3.8%; and at 3 years, 30.7%, 10.4% and 0% (P < 0.001; <a class="elsevierStyleCrossRef" href="#fig0002">Fig. 2</a>A). Median OS in this cohort was 17.0 months after liver resection, 14 months after TACE, and 7.0 months after sorafenib.<elsevierMultimedia ident="fig0002"></elsevierMultimedia>Similarly, OS rates in the internal validation cohort were significantly longer after liver resection than after TACE or sorafenib: the respective rates at 1 year were 64.3%, 47.4% and 23.5%; at 2 years, 38.6%, 27.3% and 3.9%; and at 3 years, 31.8%, 18.2% and 0% (P < 0.001; <a class="elsevierStyleCrossRef" href="#fig0002">Fig. 2</a>B). Median OS in this cohort was 16 months after liver resection, 12 months after TACE, and 7 months after sorafenib. These results suggest that, surgery is the best treatment for all PVTT types of HCC patients.3.3OS for different PVTT types in the training cohortAmong patients who underwent liver resection in the training cohort, OS rates were significantly higher among those with type I or II PVTT than among those with type III or IV PVTT: the corresponding rates at 1 year were 86.7%, 82.3%, 57.9%, and 28.6%; at 2 years, 62.7%, 49.2%, 10.5%, and 0%; and at 3 years, 55.6%, 35.9%, 5.3%, and 0%. Median OS was 28, 23, 13 and 10.5 months for the four types of PVTT (<a class="elsevierStyleCrossRef" href="#fig0003">Fig. 3</a>A).<elsevierMultimedia ident="fig0003"></elsevierMultimedia>Among patients who underwent TACE, OS was also significantly worse among those with type IV PVTT than among those with types I, II or III: the corresponding rates at 1 year were 23.8%, 64.3%, 65.6%, and 65.8%; at 2 years, 0%, 40.8%, 32.1%, and 34.0%; and at 3 years, 0%, 27.2%, 12.2%, and 5.1%. Median OS was 16, 18, 17 and 7 months for the four types of PVTT (<a class="elsevierStyleCrossRef" href="#fig0003">Fig. 3</a>B).Among patients who received sorafenib, OS did not differ significantly among the subgroups with different PVTT types, and median OS varied slightly from 5 to 8 months across the subgroups (<a class="elsevierStyleCrossRef" href="#fig0003">Fig. 3</a>C).Among patients with type I or II PVTT, liver resection was associated with markedly better OS than TACE or sorafenib (<a class="elsevierStyleCrossRef" href="#fig0004">Fig. 4</a>A, <a class="elsevierStyleCrossRef" href="#fig0004">4</a>B). In contrast, among patients with type III PVTT, TACE gave significantly better OS than liver resection or sorafenib (<a class="elsevierStyleCrossRef" href="#fig0004">Fig. 4</a>C). Among patients with type IV PVTT, the three treatments did not differ significantly (<a class="elsevierStyleCrossRef" href="#fig0004">Fig. 4</a>D).<elsevierMultimedia ident="fig0004"></elsevierMultimedia>3.4OS for different PVTT types in the internal validation cohortAmong patients who underwent liver resection in the internal validation cohort, OS was significantly higher among those with type I or II PVTT than among those with type III or IV PVTT: the corresponding rates at 1 year were 73.8%, 72.9%, 56.5%, and 23.1%; at 2 years, 48.9%, 45.9%, 26.0%, and 0%; and at 3 years, 43.7%, 32.4%, 17.4%, and 0%. Median survival was 24, 23, 14 and 11 months for patients with PVTT types I-IV (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 5</a>A).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Among patients who underwent TACE, OS was also significantly worse among those with type IV PVTT than among those with types I, II or III: the corresponding rates at 1 year were 10.8%, 54.5%, 58.3%, and 58.8%; at 2 years, 0%, 36.4%, 40.1%, and 39.9%; and at 3 years, 0%, 18.2%, 20.1%, and 20.4%. Median survival was 17, 16, 14 and 5 months for PVTT types I-IV (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 5</a>B).Among patients who received sorafenib, OS did not differ significantly among the subgroups with different PVTT types, with median OS varying slightly between 6 and 9 months (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 5</a>C). These results are consistent with those from the training cohort.Among patients with type I or II PVTT, liver resection was associated with significantly longer survival than TACE or sorafenib (<a class="elsevierStyleCrossRef" href="#fig0006">Fig. 6</a>A, <a class="elsevierStyleCrossRef" href="#fig0006">6</a>B). Among patients with type III PVTT, TACE was associated with better OS than the other two treatments (<a class="elsevierStyleCrossRef" href="#fig0006">Fig. 6</a>C). Among patients with type IV PVTT, OS did not differ significantly among the three treatments (<a class="elsevierStyleCrossRef" href="#fig0006">Fig. 6</a>D). These results are consistent with those for the training cohort.<elsevierMultimedia ident="fig0006"></elsevierMultimedia>Taken together, our results suggest that, liver resection may be more appropriate for type I or II PVTT; TACE, for type III; and sorafenib, for type IV. Evaluation of PVTT subtypes of HCC patients is of great significance in future clinical practice, and could provide potential treatment strategies for HCC patients with PVTT.4DiscussionOur results suggest that liver resection may be associated with better OS than TACE or sorafenib for HCC patients with type I or II PVTT. In contrast, TACE may be more effective for HCC patients with type III PVTT, while sorafenib may be more appropriate for patients with type IV PVTT.The optimal treatment for HCC patients with PVTT remains controversial. Some studies have highlighted the benefits of surgical treatment <a class="elsevierStyleCrossRefs" href="#bib0014">[14–17]</a>, since liver resection can unblock portal venous flow to decrease portal venous pressure and improve liver function, which can prolong survival and improve quality of life <a class="elsevierStyleCrossRef" href="#bib0007">[7]</a>. One study found that liver resection led to better outcomes than TACE for the treatment of HCC with PVTT <a class="elsevierStyleCrossRef" href="#bib0018">[18]</a>, but the other study of a larger cohort found the opposite result <a class="elsevierStyleCrossRef" href="#bib0009">[9]</a>. Our study helps explain the controversy in the literature by demonstrating that the best treatment may depend on the PVTT type. For example, we found that HCC patients with type I or II PVTT showed better OS after liver resection than after the other two treatments, consistent with a Japanese study <a class="elsevierStyleCrossRef" href="#bib0007">[7]</a>.Our results support the efficacy of TACE for treating HCC patients with type III PVTT. TACE blocks blood vessels that carry nutrients to the tumor, allowing chemotherapy to be delivered at high concentrations to cancer cells, while minimizing damage to healthy liver cells. TACE also reduces portal venous pressure and prevents formation of intractable ascites and bleeding esophageal varices <a class="elsevierStyleCrossRef" href="#bib0019">[19]</a>. In addition, our results suggest that for HCC patients with type IV PVTT, sorafenib may be preferable to resection or TACE given that it is non-invasive and associated with fewer complications than invasive treatments <a class="elsevierStyleCrossRef" href="#bib0020">[20]</a>. However, the drug should be used with caution given that it has been associated with greater risk of in-hospital mortality, high blood pressure, skin toxicity, and adverse gastrointestinal reactions [<a class="elsevierStyleCrossRef" href="#bib0006">6</a>,<a class="elsevierStyleCrossRef" href="#bib0021">21</a>]. In addition, sorafenib is not well tolerated in patients with reduced liver function <a class="elsevierStyleCrossRef" href="#bib0006">[6]</a>.Sorafenib is multi-kinase inhibitor that is approved for first-line treatment of patients with advanced hepatocellular carcinoma. However, the efficacy of targeted agents is modest, and they confer limited survival benefits. Immunotherapies, including PD -1 and PD-L1 inhibitors, have shown clinical benefits in various cancers. However, several phase 3 studies did not show superiority of anti-PD-1 monotherapy compared with standard of care for the first-line or second-line treatment of hepatocellular carcinoma <a class="elsevierStyleCrossRef" href="#bib0022">[22]</a>. Considering differences in the treatment efficacy of PD-1 and PD-L1 inhibitors across various tumor types, combination treatment with an anti-PD-1 antibody and an anti-angiogenesis agent might be a potential first-line treatment for patients with hepatocellular carcinoma. Ren et al reported [23] that compared with similar studies of first-line therapies for patients with advanced hepatocellular carcinoma, Sintilimab–bevacizumab biosimilar reduced the risk of death and disease progression. Sintilizumab-bevacizumab might be the first-line therapy for patients with advanced hepatocellular carcinoma, however, for the population of HCC patients with PVTT, the potential benefit of Sintilizumab-bevacizumab therapy is not known, Whether HCC patients with PVTT could benefit from Sintilizumab-bevacizumab therapy warrants future large cohort studies.While our retrospective analysis should be interpreted carefully given the risk of selection bias. In addition, the data could be affected by the differences in standards in surgical techniques and perioperative managements. And last, high prevalence of hepatitis B virus (HBV) may limit extrapolation of results to other patients.5ConclusionIn conclusion, our study suggested that the optimal treatment for HCC patients with PVTT may depend on their PVTT type. Liver resection may be more appropriate for type I or II PVTT; TACE, for type III; and sorafenib, for type IV. Our results underscore the importance of evaluating the PVTT subtypes of HCC tumors in future clinical practice and provide a potential treatment strategy for HCC patients with PVTT.CRediT authorship contribution statementYu Zhang: Funding acquisition, Formal analysis, Data curation, Writing – original draft, Writing – review & editing. Jun-Li Wu: Writing – original draft, Writing – review & editing. Le-Qun Li: Conceptualization, Data curation." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1716464" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abss0001" "titulo" => "Introduction and objectives" ] 1 => array:2 [ "identificador" => "abss0002" "titulo" => "Materials and methods" ] 2 => array:2 [ "identificador" => "abss0003" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abss0004" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1517075" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xpalclavsec1517074" "titulo" => "Abbreviations" ] 3 => array:2 [ "identificador" => "sec0001" "titulo" => "Introduction" ] 4 => array:3 [ "identificador" => "sec0002" "titulo" => "Material and methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0003" "titulo" => "Study population" ] 1 => array:2 [ "identificador" => "sec0004" "titulo" => "PVTT Diagnostics" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "The inclusion and exclusion criteria" ] 3 => array:2 [ "identificador" => "sec0006" "titulo" => "Procedures" ] 4 => array:2 [ "identificador" => "sec0007" "titulo" => "Follow-up" ] 5 => array:2 [ "identificador" => "sec0008" "titulo" => "Statistical analyses" ] ] ] 5 => array:3 [ "identificador" => "sec0009" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "Characteristics of Patients" ] 1 => array:2 [ "identificador" => "sec0011" "titulo" => "OS across all PVTT types" ] 2 => array:2 [ "identificador" => "sec0012" "titulo" => "OS for different PVTT types in the training cohort" ] 3 => array:2 [ "identificador" => "sec0013" "titulo" => "OS for different PVTT types in the internal validation cohort" ] ] ] 6 => array:2 [ "identificador" => "sec0014" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0015" "titulo" => "Conclusion" ] 8 => array:2 [ "identificador" => "sec0015a" "titulo" => "CRediT authorship contribution statement" ] 9 => array:2 [ "identificador" => "xack605497" "titulo" => "Acknowledgments" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-06-03" "fechaAceptado" => "2021-08-06" "PalabrasClave" => array:1 [ "en" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1517075" "palabras" => array:4 [ 0 => "Sorafenib" 1 => "Overall survival" 2 => "Liver resection" 3 => "Transarterial chemoembolization" ] ] 1 => array:4 [ "clase" => "abr" "titulo" => "Abbreviations" "identificador" => "xpalclavsec1517074" "palabras" => array:10 [ 0 => "PVTT" 1 => "HCC" 2 => "BCLC" 3 => "TACE" 4 => "LR" 5 => "OS" 6 => "MRI" 7 => "AFP" 8 => "HBV" 9 => "HCV" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "Introduction and objectivesOptimal treatment of hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) remains controversial. Materials and methodsA total of 627 HCC patients with PVTT after initial treatment with one of the following at Affiliated Tumor Hospital of Guangxi Medical University: liver resection (LR, n = 225), transarterial chemoembolization (TACE, n = 298) or sorafenib (n = 104) were recruited and randomly divided into the training cohort (n = 314) and internal validation cohort (n = 313). Survival analysis were repeated after stratifying patients by Cheng PVTT type. ResultsResection led to significantly higher OS than the other two treatments among patients with type I or II PVTT. TACE worked significantly better than the other two treatments for patients with type III. All three treatments were associated with similar OS among patients with type IV. These findings were supported by the internal validation cohort. ConclusionsOur results suggest that the optimal treatment for HCC involving PVTT depends on the type of PVTT. LR may be more appropriate for type I or II PVTT; TACE, for type III Sorafenib may be more appropriate than invasive treatments for patients with type IV PVTT." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abss0001" "titulo" => "Introduction and objectives" ] 1 => array:2 [ "identificador" => "abss0002" "titulo" => "Materials and methods" ] 2 => array:2 [ "identificador" => "abss0003" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abss0004" "titulo" => "Conclusions" ] ] ] ] "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "1" "nota" => "These authors contributed equally to the manuscript." "identificador" => "fn1" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<elsevierMultimedia ident="ecom0001"></elsevierMultimedia>" "etiqueta" => "Appendix" "titulo" => "Supplementary materials" "identificador" => "sec0017" ] ] ] ] "multimedia" => array:8 [ 0 => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2548 "Ancho" => 2167 "Tamanyo" => 408832 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Flowchart of patient selection. “Type” refers to the PVTT type according to the Cheng's classification system. HCC, hepatocellular carcinoma; LR, liver resection; PVTT, portal vein tumor thrombus." ] ] 1 => array:8 [ "identificador" => "fig0002" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 956 "Ancho" => 2500 "Tamanyo" => 180364 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0002" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Overall survival rates for HCC patients with PVTT after liver resection, TACE or sorafenib in the (A) training cohort and (B) internal validation cohort." ] ] 2 => array:8 [ "identificador" => "fig0003" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 733 "Ancho" => 3000 "Tamanyo" => 187639 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0003" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Overall survival rates for HCC patients from the training cohort with different types of portal vein tumor thrombus: patients underwent (A) liver resection, (B) TACE or (C) sorafenib." ] ] 3 => array:8 [ "identificador" => "fig0004" "etiqueta" => "Fig. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1573 "Ancho" => 2167 "Tamanyo" => 257044 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0004" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Comparison of overall survival rates for HCC patients in the training cohort who were treated using liver resection, TACE or sorafenib and were stratified by PVTT type: (A) type I, (B) type II, (C) type III, and (D) type IV." ] ] 4 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 760 "Ancho" => 3000 "Tamanyo" => 176743 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0005" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Overall survival rates for HCC patients from the internal validation cohort with different types of portal vein tumor thrombus: patients underwent (A) liver resection, (B) TACE or (C) sorafenib." ] ] 5 => array:8 [ "identificador" => "fig0006" "etiqueta" => "Fig. 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 1769 "Ancho" => 2333 "Tamanyo" => 275301 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0006" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Comparison of overall survival rates for HCC patients from the internal validation cohort who were treated using liver resection, TACE or sorafenib and were stratified by PVTT type: (A) type I, (B) type II, (C) type III, and (D) type IV." ] ] 6 => array:8 [ "identificador" => "tbl0001" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0007" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Values are n or n (%) or mean ± SD; ALB, albumin; ALT, alanine aminotransferase; PT, prothrombin time; AFP, alpha fetoprotein." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><a name="en0001"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0002"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Training cohort \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0003"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Internal validation cohort \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0004"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">P \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><a name="en0005"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">N \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0006"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">314 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0007"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">313 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0008"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0009"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Sex, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0010"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0011"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0012"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.048 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0013"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Male \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0014"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">263(83.8) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0015"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">280 (89.5) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0016"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0017"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Female \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0018"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">51 (16.2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0019"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">33 (10.5) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0020"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0021"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Age, mean ± SD \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0022"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">52.1 ± 10.9 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0023"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">49.3 ± 13.1 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0024"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.589 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0025"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Tumor size, mean ± SD \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0026"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">4.7 ± 4.9 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0027"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">5.5 ± 3.2 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0028"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.162 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0029"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Tumor number, (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0030"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0031"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0032"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.521 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0033"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Single \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0034"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">261 (83.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0035"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">253 (80.8) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0036"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0037"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Multiple \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0038"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">53 (16.9) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0039"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">60 (19.2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0040"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0041"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">HBsAg, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0042"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0043"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0044"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.113 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0045"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0046"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">58 (18.5) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0047"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">75 (23.9) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0048"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0049"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0050"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">256 (81.5) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0051"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">238 (76.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0052"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0053"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Hepatitis C antibody, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0054"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0055"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0056"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.410 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0057"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0058"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">304 (97.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0059"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">298 (95.2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0060"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0061"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0062"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">10 (2.9) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0063"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">15 (4.8) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0064"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0065"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Cirrhosis, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0066"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0067"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0068"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.215 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0069"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Absent \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0070"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">155 (49.3) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0071"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">171 (57.8) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0072"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0073"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Present \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0074"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">159 (50.7) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0075"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">142 (42.2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0076"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0077"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">AFP, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0078"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0079"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0080"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.077 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0081"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">≥400 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0082"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">273 (86.9) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0083"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">255 (81.4) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0084"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0085"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><400 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0086"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">41 (13.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0087"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">58 (18.6) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0088"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0089"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">ALB, mean ± SD \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0090"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">39.1 ± 10.65 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0091"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">36.8 ±9.1 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0092"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.081 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0093"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">Child Pugh, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0094"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0095"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0096"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.027 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0097"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0098"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">240 (76.7) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0099"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">263 (84.0) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0100"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0101"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0102"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">73 (23.3) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0103"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">50 (16.0) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0104"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2913897.png" ] ] ] ] "descripcion" => array:1 [ "en" => ". Baseline characteristics of patients with HCC with portal vein tumor thrombus." ] ] 7 => array:6 [ "identificador" => "ecom0001" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0008" "detalle" => "Image, application " "rol" => "short" ] ] "Ecomponente" => array:2 [ "fichero" => "mmc1.docx" "ficheroTamanyo" => 17939 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec1" "bibliografiaReferencia" => array:22 [ 0 => array:3 [ "identificador" => "bib0001" "etiqueta" => "[1]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer statistics, 2017" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.L. Siegel" 1 => "K.D. Miller" 2 => "A. Jemal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3322/caac.21387" "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2017" "volumen" => "67" "paginaInicial" => "7" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28055103" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0002" "etiqueta" => "[2]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Rodríguez-Perálvarez" 1 => "T.V. Luong" 2 => "L. Andreana" 3 => "T. Meyer" 4 => "A.P. Dhillon" 5 => "A.K. Burroughs" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1245/s10434-012-2513-1" "Revista" => array:6 [ "tituloSerie" => "Ann Surg Oncol" "fecha" => "2012" "volumen" => "20" "paginaInicial" => "325" "paginaFinal" => "339" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23149850" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0003" "etiqueta" => "[3]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombusa multicenter study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "X. Xiang" 1 => "W.Y. Lau" 2 => "Z.Y. Wu" 3 => "C. Zhao" 4 => "Y.L. Ma" 5 => "B.D. Xiang" 6 => "J.Y. Zhu" 7 => "J.H. Zhong" 8 => "L.Q. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejso.2019.03.042" "Revista" => array:6 [ "tituloSerie" => "Eur J Surg Oncol" "fecha" => "2019" "volumen" => "45" "paginaInicial" => "1460" "paginaFinal" => "1467" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31005471" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0004" "etiqueta" => "[4]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.M. Llovet" 1 => "A. Burroughs" 2 => "J. Bruix" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet North Am Ed" "fecha" => "2003" "volumen" => "362" "paginaInicial" => "1907" "paginaFinal" => "1917" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0005" "etiqueta" => "[5]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Josep M. Llovet" 1 => "Sergio Ricci" 2 => "Vincenzo Mazzaferro" 3 => "Philip Hilgard" 4 => "Edward Gane" 5 => "Jean-Frédéric Blanc" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(08)70285-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "25" "paginaFinal" => "34" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19095497" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0006" "etiqueta" => "[7]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Kokudo" 1 => "K. Hasegawa" 2 => "Y. Matsuyama" 3 => "T. Takayama" 4 => "N. Izumi" 5 => "M. Kadoya" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2016.05.044" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2016" "volumen" => "65" "paginaInicial" => "938" "paginaFinal" => "943" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27266618" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0007" "etiqueta" => "[8]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Lee" 1 => "B.K. Jang" 2 => "Y.J. Lee" 3 => "W.Y. Choi" 4 => "S.M. Choi" 5 => "W.J. Chung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3350/cmh.2016.22.1.160" "Revista" => array:6 [ "tituloSerie" => "Clin Mol Hepatol" "fecha" => "2016" "volumen" => "22" "paginaInicial" => "160" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27044767" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0008" "etiqueta" => "[9]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.E. Chung" 1 => "J.H. Lee" 2 => "H.Y. Kim" 3 => "S.Y. Hwang" 4 => "J.S. Kim" 5 => "J.W. Chung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiol.10101058" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "2011" "volumen" => "258" "paginaInicial" => "627" "paginaFinal" => "634" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21273524" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0009" "etiqueta" => "[10]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T. Yau" 1 => "V.Y.F. Tang" 2 => "T.-J. Yao" 3 => "S.-T. Fan" 4 => "C.-M. Lo" 5 => "R.T.P. Poon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2014.02.032" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2014" "volumen" => "146" "paginaInicial" => "1691" "paginaFinal" => "1700" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24583061" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0010" "etiqueta" => "[11]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "X. Xiang" 1 => "H.G. Qin" 2 => "X.M. You" 3 => "Y.Y. Wang" 4 => "L.N. Qi" 5 => "L. Ma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cam4.1176" "Revista" => array:6 [ "tituloSerie" => "Cancer Med" "fecha" => "2017" "volumen" => "6" "paginaInicial" => "2357" "paginaFinal" => "2369" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28941211" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0011" "etiqueta" => "[12]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Kudo" 1 => "R.S. Finn" 2 => "S. Qin" 3 => "K.H. Han" 4 => "K. Ikeda" 5 => "F. Piscaglia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(18)30207-1" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2018" "volumen" => "391" "paginaInicial" => "1163" "paginaFinal" => "1173" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29433850" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0165587620301014" "estado" => "S300" "issn" => "01655876" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0012" "etiqueta" => "[13]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.Q. Cheng" 1 => "M.C. Wu" 2 => "H. Chen" 3 => "F. Shen" 4 => "J.H. Yang" 5 => "G.H. Ding" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hepato-Gastroenterol" "fecha" => "2007" "volumen" => "54" "paginaInicial" => "499" "paginaFinal" => "502" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0013" "etiqueta" => "[14]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "K. Sakamoto" 1 => "H. Nagano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/hepr.12923" "Revista" => array:6 [ "tituloSerie" => "Hepatol Res" "fecha" => "2017" "volumen" => "47" "paginaInicial" => "957" "paginaFinal" => "962" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28618075" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0014" "etiqueta" => "[15]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.H. Zhong" 1 => "Y. Ke" 2 => "W.F. Gong" 3 => "B.D. Xiang" 4 => "L. Ma" 5 => "X.P. Ye" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/SLA.0000000000000236" "Revista" => array:6 [ "tituloSerie" => "Ann Surg" "fecha" => "2014" "volumen" => "260" "paginaInicial" => "329" "paginaFinal" => "340" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24096763" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0015" "etiqueta" => "[16]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Tanaka" 1 => "T. Morimoto" 2 => "Y. Yamaoka" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hepato-Gastroenterol" "fecha" => "1996" "volumen" => "43" "paginaInicial" => "637" "paginaFinal" => "643" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0016" "etiqueta" => "[17]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "X. Xiang" 1 => "J.H. Zhong" 2 => "Y.Y. Wang" 3 => "X.M. You" 4 => "L. Ma" 5 => "B.D. Xiang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12094-017-1621-6" "Revista" => array:6 [ "tituloSerie" => "Clin Transl Oncol" "fecha" => "2017" "volumen" => "19" "paginaInicial" => "891" "paginaFinal" => "897" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28160206" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0017" "etiqueta" => "[18]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A new classification for hepatocellular carcinoma with portal vein tumor thrombus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Shi" 1 => "E.C. Lai" 2 => "N. Li" 3 => "W.X. Guo" 4 => "J. Xue" 5 => "W.Y. Lau" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Hepato-Biliary-Pancreatic Sci" "fecha" => "2011" "volumen" => "18" "paginaInicial" => "74" "paginaFinal" => "80" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0018" "etiqueta" => "[19]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.Z. Ye" 1 => "Y.Q. Zhang" 2 => "H.H. Ye" 3 => "T. Bai" 4 => "L. Ma" 5 => "B.D. Xiang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.v20.i45.17141" "Revista" => array:7 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2014" "volumen" => "20" "paginaInicial" => "17141" "paginaFinal" => "17147" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25493028" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0165587620301014" "estado" => "S300" "issn" => "01655876" ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0019" "etiqueta" => "[20]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sorafenib: a review in hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Targeted Oncol" "fecha" => "2017" "volumen" => "12" "paginaInicial" => "243" "paginaFinal" => "253" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0020" "etiqueta" => "[21]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Bruix" 1 => "T. Takayama" 2 => "V. Mazzaferro" 3 => "G.-Y. Chau" 4 => "J. Yang" 5 => "M. Kudo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(15)00198-9" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "1344" "paginaFinal" => "1354" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26361969" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0021" "etiqueta" => "[22]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.S. Finn" 1 => "B.Y. Ryoo" 2 => "P. Merle" 3 => "M. Kudo" 4 => "M. Bouattour" 5 => "H.Y. Lim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.19.01307" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2020" "volumen" => "38" "paginaInicial" => "193" "paginaFinal" => "202" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31790344" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0022" "etiqueta" => "[23]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Ren" 1 => "J. Xu" 2 => "Y. Bai" 3 => "A. Xu" 4 => "S. Cang" 5 => "C. Du" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(21)00252-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2021" "volumen" => "22" "paginaInicial" => "977" "paginaFinal" => "990" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34143971" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack605497" "titulo" => "Acknowledgments" "texto" => "The authors acknowledge assistance from the staff in the Affiliated Tumor Hospital of Guangxi Medical University." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002519/v2_202205211521/en/main.assets" "Apartado" => array:4 [ "identificador" => "78265" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000002700000001/v2_202205211521/S1665268121002519/v2_202205211521/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002519?idApp=UINPBA00004N"]

Statistics

Original article

Yu Zhanga,c,1, Jun-Li Wua,1, Le-Qun Lia,b,

Corresponding author

zhuxun99118@163.comz
huxun99118@163.com

Corresponding author.

a Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

b Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, China

c Kaiyuan Langdong Hospital of Guangxi Medical University, Nanning, China

Read

1419

Times
was read the article

288

Total PDF

1131

Total HTML

Share statistics

 array:24 [
  "pii" => "S1665268121002519"
  "issn" => "16652681"
  "doi" => "10.1016/j.aohep.2021.100552"
  "estado" => "S300"
  "fechaPublicacion" => "2022-01-01"
  "aid" => "100552"
  "copyright" => "Fundaci&#243;n Cl&#237;nica M&#233;dica Sur&#44; A&#46;C&#46;"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Ann Hepatol. 2022;27:"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S1665268121002507"
    "issn" => "16652681"
    "doi" => "10.1016/j.aohep.2021.100551"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-01"
    "aid" => "100551"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Ann Hepatol. 2022;27:"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Circ&#95;0078710 promotes the development of liver cancer by upregulating TXNDC5 via miR-431-5p"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0001"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1897
              "Ancho" => 3583
              "Tamanyo" => 339140
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "alt0001"
              "detalle" => "Fig&#46; "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Circ&#95;0078710 and TXNDC5 were up-regulated in liver cancer&#46; &#40;A&#44; B&#41; The expression of circ&#95;0078710 and TXNDC5 in liver cancer tissues &#40;<span class="elsevierStyleItalic">n&#160;&#61;</span>&#160;30&#41; were tested by qRT-PCR&#46; &#40;C&#41; Western blot assay detected the expression of TXNDC5 protein&#46; &#40;D&#41; The correlation between circ&#95;0078710 and TXNDC5 expression in liver cancer tissues was analyzed by Pearson&#39;s correlation analysis&#46; &#42;&#42;&#42;<span class="elsevierStyleItalic">P</span> &#60; 0&#46;001&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Huajun Lu, Lili Gao, Jixiang Lv"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Huajun"
              "apellidos" => "Lu"
            ]
            1 => array:2 [
              "nombre" => "Lili"
              "apellidos" => "Gao"
            ]
            2 => array:2 [
              "nombre" => "Jixiang"
              "apellidos" => "Lv"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002507?idApp=UINPBA00004N"
    "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002507/v2_202205211521/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1665268121002556"
    "issn" => "16652681"
    "doi" => "10.1016/j.aohep.2021.100556"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-01"
    "aid" => "100556"
    "copyright" => "Fundaci&#243;n Cl&#237;nica M&#233;dica Sur&#44; A&#46;C&#46;"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Ann Hepatol. 2022;27:"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Causes of death in patients with Non-alcoholic Fatty Liver Disease &#40;NAFLD&#41;&#44; alcoholic liver disease and chronic viral Hepatitis B and C"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0001"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 3144
              "Ancho" => 2917
              "Tamanyo" => 550665
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "alt0001"
              "detalle" => "Fig&#46; "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Percent distribution of the common cause of cancer death&#44; by different chronic liver disease&#58; United States&#44; 2018</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Pegah Golabi, James M&#46; Paik, Katherine Eberly, Leyla de Avila, Saleh A&#46; Alqahtani, Zobair M&#46; Younossi"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Pegah"
              "apellidos" => "Golabi"
            ]
            1 => array:2 [
              "nombre" => "James M&#46;"
              "apellidos" => "Paik"
            ]
            2 => array:2 [
              "nombre" => "Katherine"
              "apellidos" => "Eberly"
            ]
            3 => array:2 [
              "nombre" => "Leyla"
              "apellidos" => "de Avila"
            ]
            4 => array:2 [
              "nombre" => "Saleh A&#46;"
              "apellidos" => "Alqahtani"
            ]
            5 => array:2 [
              "nombre" => "Zobair M&#46;"
              "apellidos" => "Younossi"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002556?idApp=UINPBA00004N"
    "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002556/v2_202205211521/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus"
    "tieneTextoCompleto" => true
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Yu Zhang, Jun-Li Wu, Le-Qun Li"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Yu"
            "apellidos" => "Zhang"
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0001"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0003"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn1"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Jun-Li"
            "apellidos" => "Wu"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0001"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn1"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Le-Qun"
            "apellidos" => "Li"
            "email" => array:2 [
              0 => "zhuxun99118@163.comz"
              1 => "huxun99118@163.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0001"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0002"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0001"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Department of Hepatobiliary Surgery&#44; Affiliated Tumor Hospital of Guangxi Medical University&#44; Nanning&#44; China"
            "etiqueta" => "a"
            "identificador" => "aff0001"
          ]
          1 => array:3 [
            "entidad" => "Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center&#44; Nanning&#44; China"
            "etiqueta" => "b"
            "identificador" => "aff0002"
          ]
          2 => array:3 [
            "entidad" => "Kaiyuan Langdong Hospital of Guangxi Medical University&#44; Nanning&#44; China"
            "etiqueta" => "c"
            "identificador" => "aff0003"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0001"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0002"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 956
            "Ancho" => 2500
            "Tamanyo" => 180364
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0002"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara002" class="elsevierStyleSimplePara elsevierViewall">Overall survival rates for HCC patients with PVTT after liver resection&#44; TACE or sorafenib in the &#40;A&#41; training cohort and &#40;B&#41; internal validation cohort&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">1</span><span class="elsevierStyleSectionTitle" id="cesectitle0008">Introduction</span><p id="para0006" class="elsevierStylePara elsevierViewall">Portal vein tumor thrombus &#40;PVTT&#41; occurs in 40-60&#37; of patients with hepatocellular carcinoma &#40;HCC&#41;&#44; which accounts for 80-90&#37; of cases of primary liver cancer <a class="elsevierStyleCrossRef" href="#bib0001">&#91;1&#93;</a>&#46; PVTT is a significant predictor of poor prognosis for HCC patients &#91;<a class="elsevierStyleCrossRef" href="#bib0002">2</a>&#44;<a class="elsevierStyleCrossRef" href="#bib0003">3</a>&#93;&#46; Indeed&#44; HCC patients with PVTT survive a median of 3-4 months without intervention <a class="elsevierStyleCrossRef" href="#bib0004">&#91;4&#93;</a>&#46;</p><p id="para0007" class="elsevierStylePara elsevierViewall">The optimal treatment for HCC patients with PVTT remains controversial&#46; Currently the only officially recommended treatment is sorafenib&#44; based on the Barcelona Clinic for Liver Cancer &#40;BCLC&#41; staging system <a class="elsevierStyleCrossRef" href="#bib0005">&#91;5&#93;</a>&#46; However&#44; the drug shows limited efficacy&#58; one trial reported median survival of only 6&#46;5 months in HCC patients with PVTT on the drug <a class="elsevierStyleCrossRef" href="#bib0006">&#91;6&#93;</a>&#46; This&#44; coupled with the drug&#39;s high price&#44; leads many patients to refuse the treatment and opt instead for liver resection or transarterial chemoembolization &#40;TACE&#41;&#46; Liver resection has been associated with 1-year overall survival &#40;OS&#41; rates of 22-70&#37; for HCC patients with PVTT&#44; which may be higher than with non-surgical treatments &#91;<a class="elsevierStyleCrossRef" href="#bib0007">7</a>&#44;<a class="elsevierStyleCrossRef" href="#bib0008">8</a>&#93;&#46; TACE has also proven safe and effective for such patients &#91;<a class="elsevierStyleCrossRef" href="#bib0003">3</a>&#44;<a class="elsevierStyleCrossRef" href="#bib0009">9</a>&#93;&#59; In fact&#44; the Hong Kong Liver Cancer system recommends TACE for patients with intrahepatic vascular invasion <a class="elsevierStyleCrossRef" href="#bib0010">&#91;10&#93;</a>&#46;</p><p id="para0008" class="elsevierStylePara elsevierViewall">Combined targeted therapy had received great attention from clinicians in recent years&#46; The combination targeted therapy may cover more molecular targets&#44; effectively kill tumors&#44; and weaken tumor proliferation and metastasis <a class="elsevierStyleCrossRef" href="#bib0011">&#91;11&#93;</a>&#46; However&#44; there are also some issues&#46; First&#44; the high price makes it unbearable for many HCC patients&#46; Then&#44; combined targeted therapy may be accompanied by more and more complicated complications&#46; At last&#44; the tumor may develop more complicated drug resistance to the combination targeted therapy <a class="elsevierStyleCrossRef" href="#bib0012">&#91;12&#93;</a>&#46;</p><p id="para0009" class="elsevierStylePara elsevierViewall">In this retrospective study&#44; we compared OS of HCC patients with PVTT following initial liver resection&#44; TACE or sorafenib in order to identify more effective treatments&#46; We repeated the comparison after stratifying patients by extent of portal invasion according to Cheng&#39;s PVTT classification <a class="elsevierStyleCrossRef" href="#bib0013">&#91;13&#93;</a>&#46;</p></span><span id="sec0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2</span><span class="elsevierStyleSectionTitle" id="cesectitle0009">Material and methods</span><span id="sec0003" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;1</span><span class="elsevierStyleSectionTitle" id="cesectitle0010">Study population</span><p id="para0010" class="elsevierStylePara elsevierViewall">From January 2015 to December 2019&#44; a total of 855 HCC patients with PVTT were conducted at the Affiliated Tumor Hospital of Guangxi Medical University after initial treatment with one of the following at our hospital&#58; liver resection &#40;LR&#41;&#44; transarterial chemoembolization &#40;TACE&#41; or sorafenib&#46;</p><p id="para0011" class="elsevierStylePara elsevierViewall">A total of 627 HCC patients with PVTT met the inclusion criteria and were randomly divided into the training cohort &#40;n&#160;&#61;&#160;314&#41; and internal validation cohort &#40;n&#160;&#61;&#160;313&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0001">Fig&#46;&#160;1</a>&#41;&#46; The method of random grouping is through&#8220;sample &#40;&#41;&#8221;function of R studio&#46; The details are as follows&#44; &#8220;Patients&#95;data &#60;- read&#46;table &#40;&#8764; dirict&#41; Grouping &#60;- function &#40;Patients&#95;data&#44; m&#44; n&#41; &#123;k &#61;1 while &#40;k&#60;&#61;&#40;n-1&#41;&#41; &#123;Grouping &#60;- sample &#40;Patients&#95;data&#44; m&#44; replace&#160;&#61;&#160;FALSE&#44; prob&#160;&#61;&#160;NULL&#41; for &#40;i in 1&#58;m&#41; &#123;Patients&#95;data &#60;- Patients&#95;data &#91;-which &#40;Patients&#95;data &#61;&#61; Grouping &#91;i&#93;&#41;&#93;&#125; k&#61;k&#43;1 Print &#40;Grouping&#41;&#125; Print &#40;Patients&#95;data&#41;&#125; m&#58; the number of patients in each group&#59; n&#58; the number of groups&#8221; The study was approved by the Ethics Committees of the Affiliated Tumor Hospital of Guangxi Medical University&#46; Written informed consent was obtained from all patients for their data to be used for scientific purposes&#46;</p><elsevierMultimedia ident="fig0001"></elsevierMultimedia></span><span id="sec0004" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;2</span><span class="elsevierStyleSectionTitle" id="cesectitle0011">PVTT Diagnostics</span><p id="para0012" class="elsevierStylePara elsevierViewall">HCC patients were diagnosed with PVTT based on typical preoperative radiological feature&#58; ultrasonography&#44; Doppler ultrasonography&#44; computed tomography &#40;CT&#41;&#44; magnetic resonance imaging &#40;MRI&#41;&#44; and intra- or postoperative histopathology examinations&#46; PVTT type was assigned using Cheng&#39;s classification <a class="elsevierStyleCrossRef" href="#bib0013">&#91;13&#93;</a>&#58; in type I&#44; a tumor thrombus lies in the segmental branches of the main portal vein or above&#59; in type II&#44; a tumor thrombus extends into the right or left portal vein&#59; in type III&#44; a tumor thrombus extends into the main portal vein&#59; and in type IV&#44; a tumor thrombus extends into the main portal vein and superior mesenteric vein&#46; Thus&#44; type I and II PVTT were limited to a first-order branch of the main portal vein or above &#40;Table S1&#41;&#46;</p></span><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;3</span><span class="elsevierStyleSectionTitle" id="cesectitle0012">The inclusion and exclusion criteria</span><p id="para0013" class="elsevierStylePara elsevierViewall">The inclusion criteria&#58; &#40;1&#41; they had been diagnosed with PVTT as described above&#59; &#40;2&#41; they did not show macroscopic hepatic vein tumor thrombus&#44; macroscopic bile duct tumor thrombus&#44; extrahepatic spread&#44; or distant metastasis&#59; &#40;3&#41; they did not have any other associated malignancies&#59; and &#40;4&#41; their initial treatment was liver resection&#44; TACE or sorafenib at our hospital between January 2015 and December 2019&#46; The exclusion criteria&#58; &#40;1&#41; Patients were excluded if they had Child-Pugh class C liver function&#59; &#40;2&#41; Patients had undergone palliative tumor resection&#59; &#40;3&#41; Patients medical records were incomplete&#46; The same inclusion and exclusion criteria were applied to the training and internal validation cohorts&#46;</p></span><span id="sec0006" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;4</span><span class="elsevierStyleSectionTitle" id="cesectitle0013">Procedures</span><p id="para0014" class="elsevierStylePara elsevierViewall">Liver resection was offered only to patients with Child-Pugh A function or to certain patients with Child-Pugh B liver function &#40;score &#8804;7&#41;&#46; Surgical procedures were conducted as described in this paper <a class="elsevierStyleCrossRef" href="#bib0012">&#91;12&#93;</a>&#46; For TACE&#44; a microcatheter was introduced and directed into the feeding artery&#46; An emulsion of 5-15 mL of lipiodol and 5-fluorouracil &#40;500 mg&#47;m2&#41; with or without Adriamycin &#40;30 mg&#47;m2&#41; was infused into the feeding artery&#46; Tumor response to TACE was assessed one month later using computed tomography &#40;CT&#41; and&#47;or MRI&#46; TACE was repeated once every 1-2 months for a total of 2-6 cycles&#46; HCC patients in the sorafenib group were required to receive oral sorafenib 400 mg twice daily until unacceptable toxicity or loss of clinical benefit&#46;</p></span><span id="sec0007" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;5</span><span class="elsevierStyleSectionTitle" id="cesectitle0014">Follow-up</span><p id="para0015" class="elsevierStylePara elsevierViewall">After treatment&#44; patients were followed up every 3-4 months until death or loss to follow-up&#46; On follow-up visits&#44; patients were tested for alpha-fetoprotein &#40;AFP&#41; level&#44; liver function&#44; and blood tests&#44; and they were subjected to abdominal ultrasonography&#44; contrast-enhanced CT&#44; and&#47;or MRI&#46;</p></span><span id="sec0008" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2&#46;6</span><span class="elsevierStyleSectionTitle" id="cesectitle0015">Statistical analyses</span><p id="para0016" class="elsevierStylePara elsevierViewall">Continuous data were reported as mean &#177; SD or as median &#40;interquartile range&#41;&#44; and differences were assessed for significance using the Mann-Whitney U test&#46; Differences in categorical data were assessed for significance using the chi-squared or Fisher&#39;s exact &#40;2-tailed&#41; tests&#46; The primary endpoint was OS&#44; which was defined from the date of surgery to the date of death or last follow-up&#44; and analyzed using the Kaplan-Meier method&#46; Differences in OS were assessed using the log-rank test&#46; All statistical analyses were performed using R studio v1&#46;2&#46;0 &#40;<a href="https://rstudio.com/">https&#58;&#47;&#47;rstudio&#46;com&#47;</a>&#41; and GraphPad v7&#46;0 &#40;<a href="https://www.graphpad.com/">https&#58;&#47;&#47;www&#46;graphpad&#46;com&#47;</a>&#41;&#46; Differences associated with <span class="elsevierStyleItalic">P</span> &#60; 0&#46;05 were considered statistically significant&#46;</p></span></span><span id="sec0009" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3</span><span class="elsevierStyleSectionTitle" id="cesectitle0016">Results</span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3&#46;1</span><span class="elsevierStyleSectionTitle" id="cesectitle0017">Characteristics of Patients</span><p id="para0017" class="elsevierStylePara elsevierViewall">The median age of all patients in both cohorts was 51 years&#44; and more than 70&#37; were male or were infected with hepatitis B virus&#46; Approximately 3&#37; were infected with hepatitis C virus &#40;HCV&#41;&#46; More than 50&#37; patients had liver cirrhosis&#46; All patients had compensated liver function&#46; Most baseline clinicopathological data were similar between the training and validation cohorts&#46; Patients in the training group showed a significantly higher age as well as better liver function &#40;Child Pugh A&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0001">Table&#160;1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0001"></elsevierMultimedia></span><span id="sec0011" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3&#46;2</span><span class="elsevierStyleSectionTitle" id="cesectitle0018">OS across all PVTT types</span><p id="para0018" class="elsevierStylePara elsevierViewall">During follow-up for a median of 48 months &#40;range&#44; 23-71&#41;&#44; OS rates in the training cohort were significantly longer in patients who underwent liver resection than in those who underwent TACE or sorafenib&#58; the respective rates at 1 year were 69&#46;0&#37;&#44; 56&#46;0&#37; and 26&#46;4&#37;&#59; at 2 years&#44; 38&#46;4&#37;&#44; 23&#46;9&#37; and 3&#46;8&#37;&#59; and at 3 years&#44; 30&#46;7&#37;&#44; 10&#46;4&#37; and 0&#37; &#40;<span class="elsevierStyleItalic">P</span> &#60; 0&#46;001&#59; <a class="elsevierStyleCrossRef" href="#fig0002">Fig&#46;&#160;2</a>A&#41;&#46; Median OS in this cohort was 17&#46;0 months after liver resection&#44; 14 months after TACE&#44; and 7&#46;0 months after sorafenib&#46;</p><elsevierMultimedia ident="fig0002"></elsevierMultimedia><p id="para0019" class="elsevierStylePara elsevierViewall">Similarly&#44; OS rates in the internal validation cohort were significantly longer after liver resection than after TACE or sorafenib&#58; the respective rates at 1 year were 64&#46;3&#37;&#44; 47&#46;4&#37; and 23&#46;5&#37;&#59; at 2 years&#44; 38&#46;6&#37;&#44; 27&#46;3&#37; and 3&#46;9&#37;&#59; and at 3 years&#44; 31&#46;8&#37;&#44; 18&#46;2&#37; and 0&#37; &#40;<span class="elsevierStyleItalic">P</span> &#60; 0&#46;001&#59; <a class="elsevierStyleCrossRef" href="#fig0002">Fig&#46;&#160;2</a>B&#41;&#46; Median OS in this cohort was 16 months after liver resection&#44; 12 months after TACE&#44; and 7 months after sorafenib&#46; These results suggest that&#44; surgery is the best treatment for all PVTT types of HCC patients&#46;</p></span><span id="sec0012" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3&#46;3</span><span class="elsevierStyleSectionTitle" id="cesectitle0019">OS for different PVTT types in the training cohort</span><p id="para0020" class="elsevierStylePara elsevierViewall">Among patients who underwent liver resection in the training cohort&#44; OS rates were significantly higher among those with type I or II PVTT than among those with type III or IV PVTT&#58; the corresponding rates at 1 year were 86&#46;7&#37;&#44; 82&#46;3&#37;&#44; 57&#46;9&#37;&#44; and 28&#46;6&#37;&#59; at 2 years&#44; 62&#46;7&#37;&#44; 49&#46;2&#37;&#44; 10&#46;5&#37;&#44; and 0&#37;&#59; and at 3 years&#44; 55&#46;6&#37;&#44; 35&#46;9&#37;&#44; 5&#46;3&#37;&#44; and 0&#37;&#46; Median OS was 28&#44; 23&#44; 13 and 10&#46;5 months for the four types of PVTT &#40;<a class="elsevierStyleCrossRef" href="#fig0003">Fig&#46;&#160;3</a>A&#41;&#46;</p><elsevierMultimedia ident="fig0003"></elsevierMultimedia><p id="para0021" class="elsevierStylePara elsevierViewall">Among patients who underwent TACE&#44; OS was also significantly worse among those with type IV PVTT than among those with types I&#44; II or III&#58; the corresponding rates at 1 year were 23&#46;8&#37;&#44; 64&#46;3&#37;&#44; 65&#46;6&#37;&#44; and 65&#46;8&#37;&#59; at 2 years&#44; 0&#37;&#44; 40&#46;8&#37;&#44; 32&#46;1&#37;&#44; and 34&#46;0&#37;&#59; and at 3 years&#44; 0&#37;&#44; 27&#46;2&#37;&#44; 12&#46;2&#37;&#44; and 5&#46;1&#37;&#46; Median OS was 16&#44; 18&#44; 17 and 7 months for the four types of PVTT &#40;<a class="elsevierStyleCrossRef" href="#fig0003">Fig&#46;&#160;3</a>B&#41;&#46;</p><p id="para0022" class="elsevierStylePara elsevierViewall">Among patients who received sorafenib&#44; OS did not differ significantly among the subgroups with different PVTT types&#44; and median OS varied slightly from 5 to 8 months across the subgroups &#40;<a class="elsevierStyleCrossRef" href="#fig0003">Fig&#46;&#160;3</a>C&#41;&#46;</p><p id="para0023" class="elsevierStylePara elsevierViewall">Among patients with type I or II PVTT&#44; liver resection was associated with markedly better OS than TACE or sorafenib &#40;<a class="elsevierStyleCrossRef" href="#fig0004">Fig&#46;&#160;4</a>A&#44; <a class="elsevierStyleCrossRef" href="#fig0004">4</a>B&#41;&#46; In contrast&#44; among patients with type III PVTT&#44; TACE gave significantly better OS than liver resection or sorafenib &#40;<a class="elsevierStyleCrossRef" href="#fig0004">Fig&#46;&#160;4</a>C&#41;&#46; Among patients with type IV PVTT&#44; the three treatments did not differ significantly &#40;<a class="elsevierStyleCrossRef" href="#fig0004">Fig&#46;&#160;4</a>D&#41;&#46;</p><elsevierMultimedia ident="fig0004"></elsevierMultimedia></span><span id="sec0013" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3&#46;4</span><span class="elsevierStyleSectionTitle" id="cesectitle0020">OS for different PVTT types in the internal validation cohort</span><p id="para0024" class="elsevierStylePara elsevierViewall">Among patients who underwent liver resection in the internal validation cohort&#44; OS was significantly higher among those with type I or II PVTT than among those with type III or IV PVTT&#58; the corresponding rates at 1 year were 73&#46;8&#37;&#44; 72&#46;9&#37;&#44; 56&#46;5&#37;&#44; and 23&#46;1&#37;&#59; at 2 years&#44; 48&#46;9&#37;&#44; 45&#46;9&#37;&#44; 26&#46;0&#37;&#44; and 0&#37;&#59; and at 3 years&#44; 43&#46;7&#37;&#44; 32&#46;4&#37;&#44; 17&#46;4&#37;&#44; and 0&#37;&#46; Median survival was 24&#44; 23&#44; 14 and 11 months for patients with PVTT types I-IV &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46;&#160;5</a>A&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="para0025" class="elsevierStylePara elsevierViewall">Among patients who underwent TACE&#44; OS was also significantly worse among those with type IV PVTT than among those with types I&#44; II or III&#58; the corresponding rates at 1 year were 10&#46;8&#37;&#44; 54&#46;5&#37;&#44; 58&#46;3&#37;&#44; and 58&#46;8&#37;&#59; at 2 years&#44; 0&#37;&#44; 36&#46;4&#37;&#44; 40&#46;1&#37;&#44; and 39&#46;9&#37;&#59; and at 3 years&#44; 0&#37;&#44; 18&#46;2&#37;&#44; 20&#46;1&#37;&#44; and 20&#46;4&#37;&#46; Median survival was 17&#44; 16&#44; 14 and 5 months for PVTT types I-IV &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46;&#160;5</a>B&#41;&#46;</p><p id="para0026" class="elsevierStylePara elsevierViewall">Among patients who received sorafenib&#44; OS did not differ significantly among the subgroups with different PVTT types&#44; with median OS varying slightly between 6 and 9 months &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46;&#160;5</a>C&#41;&#46; These results are consistent with those from the training cohort&#46;</p><p id="para0027" class="elsevierStylePara elsevierViewall">Among patients with type I or II PVTT&#44; liver resection was associated with significantly longer survival than TACE or sorafenib &#40;<a class="elsevierStyleCrossRef" href="#fig0006">Fig&#46;&#160;6</a>A&#44; <a class="elsevierStyleCrossRef" href="#fig0006">6</a>B&#41;&#46; Among patients with type III PVTT&#44; TACE was associated with better OS than the other two treatments &#40;<a class="elsevierStyleCrossRef" href="#fig0006">Fig&#46;&#160;6</a>C&#41;&#46; Among patients with type IV PVTT&#44; OS did not differ significantly among the three treatments &#40;<a class="elsevierStyleCrossRef" href="#fig0006">Fig&#46;&#160;6</a>D&#41;&#46; These results are consistent with those for the training cohort&#46;</p><elsevierMultimedia ident="fig0006"></elsevierMultimedia><p id="para0028" class="elsevierStylePara elsevierViewall">Taken together&#44; our results suggest that&#44; liver resection may be more appropriate for type I or II PVTT&#59; TACE&#44; for type III&#59; and sorafenib&#44; for type IV&#46; Evaluation of PVTT subtypes of HCC patients is of great significance in future clinical practice&#44; and could provide potential treatment strategies for HCC patients with PVTT&#46;</p></span></span><span id="sec0014" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">4</span><span class="elsevierStyleSectionTitle" id="cesectitle0021">Discussion</span><p id="para0029" class="elsevierStylePara elsevierViewall">Our results suggest that liver resection may be associated with better OS than TACE or sorafenib for HCC patients with type I or II PVTT&#46; In contrast&#44; TACE may be more effective for HCC patients with type III PVTT&#44; while sorafenib may be more appropriate for patients with type IV PVTT&#46;</p><p id="para0030" class="elsevierStylePara elsevierViewall">The optimal treatment for HCC patients with PVTT remains controversial&#46; Some studies have highlighted the benefits of surgical treatment <a class="elsevierStyleCrossRefs" href="#bib0014">&#91;14&#8211;17&#93;</a>&#44; since liver resection can unblock portal venous flow to decrease portal venous pressure and improve liver function&#44; which can prolong survival and improve quality of life <a class="elsevierStyleCrossRef" href="#bib0007">&#91;7&#93;</a>&#46; One study found that liver resection led to better outcomes than TACE for the treatment of HCC with PVTT <a class="elsevierStyleCrossRef" href="#bib0018">&#91;18&#93;</a>&#44; but the other study of a larger cohort found the opposite result <a class="elsevierStyleCrossRef" href="#bib0009">&#91;9&#93;</a>&#46; Our study helps explain the controversy in the literature by demonstrating that the best treatment may depend on the PVTT type&#46; For example&#44; we found that HCC patients with type I or II PVTT showed better OS after liver resection than after the other two treatments&#44; consistent with a Japanese study <a class="elsevierStyleCrossRef" href="#bib0007">&#91;7&#93;</a>&#46;</p><p id="para0031" class="elsevierStylePara elsevierViewall">Our results support the efficacy of TACE for treating HCC patients with type III PVTT&#46; TACE blocks blood vessels that carry nutrients to the tumor&#44; allowing chemotherapy to be delivered at high concentrations to cancer cells&#44; while minimizing damage to healthy liver cells&#46; TACE also reduces portal venous pressure and prevents formation of intractable ascites and bleeding esophageal varices <a class="elsevierStyleCrossRef" href="#bib0019">&#91;19&#93;</a>&#46; In addition&#44; our results suggest that for HCC patients with type IV PVTT&#44; sorafenib may be preferable to resection or TACE given that it is non-invasive and associated with fewer complications than invasive treatments <a class="elsevierStyleCrossRef" href="#bib0020">&#91;20&#93;</a>&#46; However&#44; the drug should be used with caution given that it has been associated with greater risk of in-hospital mortality&#44; high blood pressure&#44; skin toxicity&#44; and adverse gastrointestinal reactions &#91;<a class="elsevierStyleCrossRef" href="#bib0006">6</a>&#44;<a class="elsevierStyleCrossRef" href="#bib0021">21</a>&#93;&#46; In addition&#44; sorafenib is not well tolerated in patients with reduced liver function <a class="elsevierStyleCrossRef" href="#bib0006">&#91;6&#93;</a>&#46;</p><p id="para0032" class="elsevierStylePara elsevierViewall">Sorafenib is multi-kinase inhibitor that is approved for first-line treatment of patients with advanced hepatocellular carcinoma&#46; However&#44; the efficacy of targeted agents is modest&#44; and they confer limited survival benefits&#46; Immunotherapies&#44; including PD -1 and PD-L1 inhibitors&#44; have shown clinical benefits in various cancers&#46; However&#44; several phase 3 studies did not show superiority of anti-PD-1 monotherapy compared with standard of care for the first-line or second-line treatment of hepatocellular carcinoma <a class="elsevierStyleCrossRef" href="#bib0022">&#91;22&#93;</a>&#46; Considering differences in the treatment efficacy of PD-1 and PD-L1 inhibitors across various tumor types&#44; combination treatment with an anti-PD-1 antibody and an anti-angiogenesis agent might be a potential first-line treatment for patients with hepatocellular carcinoma&#46; Ren et&#160;al reported &#91;23&#93; that compared with similar studies of first-line therapies for patients with advanced hepatocellular carcinoma&#44; Sintilimab&#8211;bevacizumab biosimilar reduced the risk of death and disease progression&#46; Sintilizumab-bevacizumab might be the first-line therapy for patients with advanced hepatocellular carcinoma&#44; however&#44; for the population of HCC patients with PVTT&#44; the potential benefit of Sintilizumab-bevacizumab therapy is not known&#44; Whether HCC patients with PVTT could benefit from Sintilizumab-bevacizumab therapy warrants future large cohort studies&#46;</p><p id="para0033" class="elsevierStylePara elsevierViewall">While our retrospective analysis should be interpreted carefully given the risk of selection bias&#46; In addition&#44; the data could be affected by the differences in standards in surgical techniques and perioperative managements&#46; And last&#44; high prevalence of hepatitis B virus &#40;HBV&#41; may limit extrapolation of results to other patients&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">5</span><span class="elsevierStyleSectionTitle" id="cesectitle0022">Conclusion</span><p id="para0034" class="elsevierStylePara elsevierViewall">In conclusion&#44; our study suggested that the optimal treatment for HCC patients with PVTT may depend on their PVTT type&#46; Liver resection may be more appropriate for type I or II PVTT&#59; TACE&#44; for type III&#59; and sorafenib&#44; for type IV&#46; Our results underscore the importance of evaluating the PVTT subtypes of HCC tumors in future clinical practice and provide a potential treatment strategy for HCC patients with PVTT&#46;</p></span><span id="sec0015a" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0022a">CRediT authorship contribution statement</span><p id="para0034a" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Yu Zhang&#58;</span> Funding acquisition&#44; Formal analysis&#44; Data curation&#44; Writing &#8211; original draft&#44; Writing &#8211; review &#38; editing&#46; <span class="elsevierStyleBold">Jun-Li Wu&#58;</span> Writing &#8211; original draft&#44; Writing &#8211; review &#38; editing&#46; <span class="elsevierStyleBold">Le-Qun Li&#58;</span> Conceptualization&#44; Data curation&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1716464"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abss0001"
              "titulo" => "Introduction and objectives"
            ]
            1 => array:2 [
              "identificador" => "abss0002"
              "titulo" => "Materials and methods"
            ]
            2 => array:2 [
              "identificador" => "abss0003"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abss0004"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1517075"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1517074"
          "titulo" => "Abbreviations"
        ]
        3 => array:2 [
          "identificador" => "sec0001"
          "titulo" => "Introduction"
        ]
        4 => array:3 [
          "identificador" => "sec0002"
          "titulo" => "Material and methods"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0003"
              "titulo" => "Study population"
            ]
            1 => array:2 [
              "identificador" => "sec0004"
              "titulo" => "PVTT Diagnostics"
            ]
            2 => array:2 [
              "identificador" => "sec0005"
              "titulo" => "The inclusion and exclusion criteria"
            ]
            3 => array:2 [
              "identificador" => "sec0006"
              "titulo" => "Procedures"
            ]
            4 => array:2 [
              "identificador" => "sec0007"
              "titulo" => "Follow-up"
            ]
            5 => array:2 [
              "identificador" => "sec0008"
              "titulo" => "Statistical analyses"
            ]
          ]
        ]
        5 => array:3 [
          "identificador" => "sec0009"
          "titulo" => "Results"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0010"
              "titulo" => "Characteristics of Patients"
            ]
            1 => array:2 [
              "identificador" => "sec0011"
              "titulo" => "OS across all PVTT types"
            ]
            2 => array:2 [
              "identificador" => "sec0012"
              "titulo" => "OS for different PVTT types in the training cohort"
            ]
            3 => array:2 [
              "identificador" => "sec0013"
              "titulo" => "OS for different PVTT types in the internal validation cohort"
            ]
          ]
        ]
        6 => array:2 [
          "identificador" => "sec0014"
          "titulo" => "Discussion"
        ]
        7 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conclusion"
        ]
        8 => array:2 [
          "identificador" => "sec0015a"
          "titulo" => "CRediT authorship contribution statement"
        ]
        9 => array:2 [
          "identificador" => "xack605497"
          "titulo" => "Acknowledgments"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2021-06-03"
    "fechaAceptado" => "2021-08-06"
    "PalabrasClave" => array:1 [
      "en" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1517075"
          "palabras" => array:4 [
            0 => "Sorafenib"
            1 => "Overall survival"
            2 => "Liver resection"
            3 => "Transarterial chemoembolization"
          ]
        ]
        1 => array:4 [
          "clase" => "abr"
          "titulo" => "Abbreviations"
          "identificador" => "xpalclavsec1517074"
          "palabras" => array:10 [
            0 => "PVTT"
            1 => "HCC"
            2 => "BCLC"
            3 => "TACE"
            4 => "LR"
            5 => "OS"
            6 => "MRI"
            7 => "AFP"
            8 => "HBV"
            9 => "HCV"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abss0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0002">Introduction and objectives</span><p id="spara009" class="elsevierStyleSimplePara elsevierViewall">Optimal treatment of hepatocellular carcinoma &#40;HCC&#41; involving portal vein tumor thrombus &#40;PVTT&#41; remains controversial&#46;</p></span> <span id="abss0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0003">Materials and methods</span><p id="spara010" class="elsevierStyleSimplePara elsevierViewall">A total of 627 HCC patients with PVTT after initial treatment with one of the following at Affiliated Tumor Hospital of Guangxi Medical University&#58; liver resection &#40;LR&#44; n&#160;&#61;&#160;225&#41;&#44; transarterial chemoembolization &#40;TACE&#44; n&#160;&#61;&#160;298&#41; or sorafenib &#40;n&#160;&#61;&#160;104&#41; were recruited and randomly divided into the training cohort &#40;n&#160;&#61;&#160;314&#41; and internal validation cohort &#40;n&#160;&#61;&#160;313&#41;&#46;&#160;Survival analysis were repeated after stratifying patients by Cheng PVTT type&#46;</p></span> <span id="abss0003" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0004">Results</span><p id="spara011" class="elsevierStyleSimplePara elsevierViewall">Resection led to significantly higher OS than the other two treatments among patients with type I or II PVTT&#46; TACE worked significantly better than the other two treatments for patients with type III&#46; All three treatments were associated with similar OS among patients with type IV&#46; These findings were supported by the internal validation cohort&#46;</p></span> <span id="abss0004" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0005">Conclusions</span><p id="spara012" class="elsevierStyleSimplePara elsevierViewall">Our results suggest that the optimal treatment for HCC involving PVTT depends on the type of PVTT&#46; LR may be more appropriate for type I or II PVTT&#59; TACE&#44; for type III Sorafenib may be more appropriate than invasive treatments for patients with type IV PVTT&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abss0001"
            "titulo" => "Introduction and objectives"
          ]
          1 => array:2 [
            "identificador" => "abss0002"
            "titulo" => "Materials and methods"
          ]
          2 => array:2 [
            "identificador" => "abss0003"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abss0004"
            "titulo" => "Conclusions"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "1"
        "nota" => "<p class="elsevierStyleNotepara" id="notep0001">These authors contributed equally to the manuscript&#46;</p>"
        "identificador" => "fn1"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="para0035a" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="ecom0001"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix"
            "titulo" => "Supplementary materials"
            "identificador" => "sec0017"
          ]
        ]
      ]
    ]
    "multimedia" => array:8 [
      0 => array:8 [
        "identificador" => "fig0001"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2548
            "Ancho" => 2167
            "Tamanyo" => 408832
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0001"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Flowchart of patient selection&#46; &#8220;Type&#8221; refers to the PVTT type according to the Cheng&#39;s classification system&#46; HCC&#44; hepatocellular carcinoma&#59; LR&#44; liver resection&#59; PVTT&#44; portal vein tumor thrombus&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig0002"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 956
            "Ancho" => 2500
            "Tamanyo" => 180364
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0002"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara002" class="elsevierStyleSimplePara elsevierViewall">Overall survival rates for HCC patients with PVTT after liver resection&#44; TACE or sorafenib in the &#40;A&#41; training cohort and &#40;B&#41; internal validation cohort&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig0003"
        "etiqueta" => "Fig&#46; 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 733
            "Ancho" => 3000
            "Tamanyo" => 187639
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0003"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara003" class="elsevierStyleSimplePara elsevierViewall">Overall survival rates for HCC patients from the training cohort with different types of portal vein tumor thrombus&#58; patients underwent &#40;A&#41; liver resection&#44; &#40;B&#41; TACE or &#40;C&#41; sorafenib&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig0004"
        "etiqueta" => "Fig&#46; 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1573
            "Ancho" => 2167
            "Tamanyo" => 257044
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0004"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara004" class="elsevierStyleSimplePara elsevierViewall">Comparison of overall survival rates for HCC patients in the training cohort who were treated using liver resection&#44; TACE or sorafenib and were stratified by PVTT type&#58; &#40;A&#41; type I&#44; &#40;B&#41; type II&#44; &#40;C&#41; type III&#44; and &#40;D&#41; type IV&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 760
            "Ancho" => 3000
            "Tamanyo" => 176743
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0005"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara005" class="elsevierStyleSimplePara elsevierViewall">Overall survival rates for HCC patients from the internal validation cohort with different types of portal vein tumor thrombus&#58; patients underwent &#40;A&#41; liver resection&#44; &#40;B&#41; TACE or &#40;C&#41; sorafenib&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig0006"
        "etiqueta" => "Fig&#46; 6"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr6.jpeg"
            "Alto" => 1769
            "Ancho" => 2333
            "Tamanyo" => 275301
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0006"
            "detalle" => "Fig "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara006" class="elsevierStyleSimplePara elsevierViewall">Comparison of overall survival rates for HCC patients from the internal validation cohort who were treated using liver resection&#44; TACE or sorafenib and were stratified by PVTT type&#58; &#40;A&#41; type I&#44; &#40;B&#41; type II&#44; &#40;C&#41; type III&#44; and &#40;D&#41; type IV&#46;</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0001"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0007"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spara008" class="elsevierStyleSimplePara elsevierViewall">Values are n or n &#40;&#37;&#41; or mean &#177; SD&#59; ALB&#44; albumin&#59; ALT&#44; alanine aminotransferase&#59; PT&#44; prothrombin time&#59; AFP&#44; alpha fetoprotein&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><a name="en0001"></a><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><a name="en0002"></a><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Training cohort&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><a name="en0003"></a><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Internal validation cohort&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><a name="en0004"></a><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><a name="en0005"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0006"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">314&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0007"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">313&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0008"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0009"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Sex&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0010"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0011"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0012"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;048&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0013"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0014"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">263&#40;83&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0015"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">280 &#40;89&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0016"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0017"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0018"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">51 &#40;16&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0019"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">33 &#40;10&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0020"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0021"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Age&#44; mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0022"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">52&#46;1 &#177; 10&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0023"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">49&#46;3 &#177; 13&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0024"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;589&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0025"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Tumor size&#44; mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0026"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">4&#46;7 &#177; 4&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0027"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">5&#46;5 &#177; 3&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0028"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;162&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0029"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Tumor number&#44; &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0030"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0031"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0032"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;521&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0033"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Single&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0034"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">261 &#40;83&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0035"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">253 &#40;80&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0036"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0037"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Multiple&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0038"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">53 &#40;16&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0039"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">60 &#40;19&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0040"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0041"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">HBsAg&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0042"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0043"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0044"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;113&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0045"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0046"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">58 &#40;18&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0047"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">75 &#40;23&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0048"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0049"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0050"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">256 &#40;81&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0051"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">238 &#40;76&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0052"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0053"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Hepatitis C antibody&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0054"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0055"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0056"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;410&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0057"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0058"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">304 &#40;97&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0059"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">298 &#40;95&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0060"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0061"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0062"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">10 &#40;2&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0063"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">15 &#40;4&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0064"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0065"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Cirrhosis&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0066"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0067"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0068"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;215&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0069"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Absent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0070"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">155 &#40;49&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0071"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">171 &#40;57&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0072"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0073"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Present&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0074"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">159 &#40;50&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0075"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">142 &#40;42&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0076"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0077"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">AFP&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0078"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0079"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0080"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;077&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0081"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8805;400&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0082"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">273 &#40;86&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0083"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">255 &#40;81&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0084"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0085"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>&#60;400&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0086"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">41 &#40;13&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0087"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">58 &#40;18&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0088"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0089"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">ALB&#44; mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0090"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">39&#46;1 &#177; 10&#46;65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0091"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">36&#46;8 &#177;9&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0092"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;081&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0093"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">Child Pugh&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0094"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0095"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0096"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">0&#46;027&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0097"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0098"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">240 &#40;76&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0099"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">263 &#40;84&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0100"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><a name="en0101"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0102"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">73 &#40;23&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0103"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">50 &#40;16&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><a name="en0104"></a><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2913897.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara007" class="elsevierStyleSimplePara elsevierViewall">&#46; Baseline characteristics of patients with HCC with portal vein tumor thrombus&#46;</p>"
        ]
      ]
      7 => array:6 [
        "identificador" => "ecom0001"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "alt0008"
            "detalle" => "Image&#44; application "
            "rol" => "short"
          ]
        ]
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.docx"
          "ficheroTamanyo" => 17939
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "cebibsec1"
          "bibliografiaReferencia" => array:22 [
            0 => array:3 [
              "identificador" => "bib0001"
              "etiqueta" => "&#91;1&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer statistics&#44; 2017"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "R&#46;L&#46; Siegel"
                            1 => "K&#46;D&#46; Miller"
                            2 => "A&#46; Jemal"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3322/caac.21387"
                      "Revista" => array:6 [
                        "tituloSerie" => "CA Cancer J Clin"
                        "fecha" => "2017"
                        "volumen" => "67"
                        "paginaInicial" => "7"
                        "paginaFinal" => "30"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28055103"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0002"
              "etiqueta" => "&#91;2&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A systematic review of microvascular invasion in hepatocellular carcinoma&#58; diagnostic and prognostic variability"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Rodr&#237;guez-Per&#225;lvarez"
                            1 => "T&#46;V&#46; Luong"
                            2 => "L&#46; Andreana"
                            3 => "T&#46; Meyer"
                            4 => "A&#46;P&#46; Dhillon"
                            5 => "A&#46;K&#46; Burroughs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1245/s10434-012-2513-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Surg Oncol"
                        "fecha" => "2012"
                        "volumen" => "20"
                        "paginaInicial" => "325"
                        "paginaFinal" => "339"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23149850"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0003"
              "etiqueta" => "&#91;3&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombusa multicenter study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:9 [
                            0 => "X&#46; Xiang"
                            1 => "W&#46;Y&#46; Lau"
                            2 => "Z&#46;Y&#46; Wu"
                            3 => "C&#46; Zhao"
                            4 => "Y&#46;L&#46; Ma"
                            5 => "B&#46;D&#46; Xiang"
                            6 => "J&#46;Y&#46; Zhu"
                            7 => "J&#46;H&#46; Zhong"
                            8 => "L&#46;Q&#46; Li"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejso.2019.03.042"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Surg Oncol"
                        "fecha" => "2019"
                        "volumen" => "45"
                        "paginaInicial" => "1460"
                        "paginaFinal" => "1467"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31005471"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0004"
              "etiqueta" => "&#91;4&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatocellular carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;M&#46; Llovet"
                            1 => "A&#46; Burroughs"
                            2 => "J&#46; Bruix"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet North Am Ed"
                        "fecha" => "2003"
                        "volumen" => "362"
                        "paginaInicial" => "1907"
                        "paginaFinal" => "1917"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "&#91;5&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma&#58; a phase III randomised&#44; double-blind&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Josep M&#46; Llovet"
                            1 => "Sergio Ricci"
                            2 => "Vincenzo Mazzaferro"
                            3 => "Philip Hilgard"
                            4 => "Edward Gane"
                            5 => "Jean-Fr&#233;d&#233;ric Blanc"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(08)70285-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2009"
                        "volumen" => "10"
                        "paginaInicial" => "25"
                        "paginaFinal" => "34"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19095497"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0006"
              "etiqueta" => "&#91;7&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Kokudo"
                            1 => "K&#46; Hasegawa"
                            2 => "Y&#46; Matsuyama"
                            3 => "T&#46; Takayama"
                            4 => "N&#46; Izumi"
                            5 => "M&#46; Kadoya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2016.05.044"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2016"
                        "volumen" => "65"
                        "paginaInicial" => "938"
                        "paginaFinal" => "943"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27266618"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0007"
              "etiqueta" => "&#91;8&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Lee"
                            1 => "B&#46;K&#46; Jang"
                            2 => "Y&#46;J&#46; Lee"
                            3 => "W&#46;Y&#46; Choi"
                            4 => "S&#46;M&#46; Choi"
                            5 => "W&#46;J&#46; Chung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3350/cmh.2016.22.1.160"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Mol Hepatol"
                        "fecha" => "2016"
                        "volumen" => "22"
                        "paginaInicial" => "160"
                        "paginaFinal" => "167"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27044767"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0008"
              "etiqueta" => "&#91;9&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;E&#46; Chung"
                            1 => "J&#46;H&#46; Lee"
                            2 => "H&#46;Y&#46; Kim"
                            3 => "S&#46;Y&#46; Hwang"
                            4 => "J&#46;S&#46; Kim"
                            5 => "J&#46;W&#46; Chung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1148/radiol.10101058"
                      "Revista" => array:6 [
                        "tituloSerie" => "Radiology"
                        "fecha" => "2011"
                        "volumen" => "258"
                        "paginaInicial" => "627"
                        "paginaFinal" => "634"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21273524"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0009"
              "etiqueta" => "&#91;10&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "T&#46; Yau"
                            1 => "V&#46;Y&#46;F&#46; Tang"
                            2 => "T&#46;-J&#46; Yao"
                            3 => "S&#46;-T&#46; Fan"
                            4 => "C&#46;-M&#46; Lo"
                            5 => "R&#46;T&#46;P&#46; Poon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2014.02.032"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2014"
                        "volumen" => "146"
                        "paginaInicial" => "1691"
                        "paginaFinal" => "1700"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24583061"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "&#91;11&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "X&#46; Xiang"
                            1 => "H&#46;G&#46; Qin"
                            2 => "X&#46;M&#46; You"
                            3 => "Y&#46;Y&#46; Wang"
                            4 => "L&#46;N&#46; Qi"
                            5 => "L&#46; Ma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cam4.1176"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Med"
                        "fecha" => "2017"
                        "volumen" => "6"
                        "paginaInicial" => "2357"
                        "paginaFinal" => "2369"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28941211"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0011"
              "etiqueta" => "&#91;12&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma&#58; a randomised phase 3 non-inferiority trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Kudo"
                            1 => "R&#46;S&#46; Finn"
                            2 => "S&#46; Qin"
                            3 => "K&#46;H&#46; Han"
                            4 => "K&#46; Ikeda"
                            5 => "F&#46; Piscaglia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)30207-1"
                      "Revista" => array:7 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2018"
                        "volumen" => "391"
                        "paginaInicial" => "1163"
                        "paginaFinal" => "1173"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29433850"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0165587620301014"
                          "estado" => "S300"
                          "issn" => "01655876"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0012"
              "etiqueta" => "&#91;13&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;Q&#46; Cheng"
                            1 => "M&#46;C&#46; Wu"
                            2 => "H&#46; Chen"
                            3 => "F&#46; Shen"
                            4 => "J&#46;H&#46; Yang"
                            5 => "G&#46;H&#46; Ding"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepato-Gastroenterol"
                        "fecha" => "2007"
                        "volumen" => "54"
                        "paginaInicial" => "499"
                        "paginaFinal" => "502"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0013"
              "etiqueta" => "&#91;14&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "K&#46; Sakamoto"
                            1 => "H&#46; Nagano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/hepr.12923"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatol Res"
                        "fecha" => "2017"
                        "volumen" => "47"
                        "paginaInicial" => "957"
                        "paginaFinal" => "962"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28618075"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0014"
              "etiqueta" => "&#91;15&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;H&#46; Zhong"
                            1 => "Y&#46; Ke"
                            2 => "W&#46;F&#46; Gong"
                            3 => "B&#46;D&#46; Xiang"
                            4 => "L&#46; Ma"
                            5 => "X&#46;P&#46; Ye"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/SLA.0000000000000236"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Surg"
                        "fecha" => "2014"
                        "volumen" => "260"
                        "paginaInicial" => "329"
                        "paginaFinal" => "340"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24096763"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "&#91;16&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Tanaka"
                            1 => "T&#46; Morimoto"
                            2 => "Y&#46; Yamaoka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepato-Gastroenterol"
                        "fecha" => "1996"
                        "volumen" => "43"
                        "paginaInicial" => "637"
                        "paginaFinal" => "643"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0016"
              "etiqueta" => "&#91;17&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "X&#46; Xiang"
                            1 => "J&#46;H&#46; Zhong"
                            2 => "Y&#46;Y&#46; Wang"
                            3 => "X&#46;M&#46; You"
                            4 => "L&#46; Ma"
                            5 => "B&#46;D&#46; Xiang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12094-017-1621-6"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Transl Oncol"
                        "fecha" => "2017"
                        "volumen" => "19"
                        "paginaInicial" => "891"
                        "paginaFinal" => "897"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28160206"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0017"
              "etiqueta" => "&#91;18&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A new classification for hepatocellular carcinoma with portal vein tumor thrombus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Shi"
                            1 => "E&#46;C&#46; Lai"
                            2 => "N&#46; Li"
                            3 => "W&#46;X&#46; Guo"
                            4 => "J&#46; Xue"
                            5 => "W&#46;Y&#46; Lau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepato-Biliary-Pancreatic Sci"
                        "fecha" => "2011"
                        "volumen" => "18"
                        "paginaInicial" => "74"
                        "paginaFinal" => "80"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0018"
              "etiqueta" => "&#91;19&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;Z&#46; Ye"
                            1 => "Y&#46;Q&#46; Zhang"
                            2 => "H&#46;H&#46; Ye"
                            3 => "T&#46; Bai"
                            4 => "L&#46; Ma"
                            5 => "B&#46;D&#46; Xiang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3748/wjg.v20.i45.17141"
                      "Revista" => array:7 [
                        "tituloSerie" => "World J Gastroenterol"
                        "fecha" => "2014"
                        "volumen" => "20"
                        "paginaInicial" => "17141"
                        "paginaFinal" => "17147"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25493028"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0165587620301014"
                          "estado" => "S300"
                          "issn" => "01655876"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0019"
              "etiqueta" => "&#91;20&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sorafenib&#58; a review in hepatocellular carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46;M&#46; Keating"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Targeted Oncol"
                        "fecha" => "2017"
                        "volumen" => "12"
                        "paginaInicial" => "243"
                        "paginaFinal" => "253"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "&#91;21&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation &#40;STORM&#41;&#58; a phase 3&#44; randomised&#44; double-blind&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Bruix"
                            1 => "T&#46; Takayama"
                            2 => "V&#46; Mazzaferro"
                            3 => "G&#46;-Y&#46; Chau"
                            4 => "J&#46; Yang"
                            5 => "M&#46; Kudo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(15)00198-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2015"
                        "volumen" => "16"
                        "paginaInicial" => "1344"
                        "paginaFinal" => "1354"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26361969"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0021"
              "etiqueta" => "&#91;22&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240&#58; a randomized&#44; double-blind&#44; phase III trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;S&#46; Finn"
                            1 => "B&#46;Y&#46; Ryoo"
                            2 => "P&#46; Merle"
                            3 => "M&#46; Kudo"
                            4 => "M&#46; Bouattour"
                            5 => "H&#46;Y&#46; Lim"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.19.01307"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2020"
                        "volumen" => "38"
                        "paginaInicial" => "193"
                        "paginaFinal" => "202"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31790344"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0022"
              "etiqueta" => "&#91;23&#93;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sintilimab plus a bevacizumab biosimilar &#40;IBI305&#41; versus sorafenib in unresectable hepatocellular carcinoma &#40;ORIENT-32&#41;&#58; a randomised&#44; open-label&#44; phase 2&#8211;3 study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Z&#46; Ren"
                            1 => "J&#46; Xu"
                            2 => "Y&#46; Bai"
                            3 => "A&#46; Xu"
                            4 => "S&#46; Cang"
                            5 => "C&#46; Du"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(21)00252-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2021"
                        "volumen" => "22"
                        "paginaInicial" => "977"
                        "paginaFinal" => "990"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34143971"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack605497"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="para0037" class="elsevierStylePara elsevierViewall">The authors acknowledge assistance from the staff in the Affiliated Tumor Hospital of Guangxi Medical University&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/16652681/0000002700000001/v2_202205211521/S1665268121002519/v2_202205211521/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "78265"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/16652681/0000002700000001/v2_202205211521/S1665268121002519/v2_202205211521/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268121002519?idApp=UINPBA00004N"
]

Article information

ISSN: 16652681
Original language: English

DOI:10.1016/j.aohep.2021.100552

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	3	0	3
2024 October	39	3	42
2024 September	41	1	42
2024 August	38	5	43
2024 July	50	5	55
2024 June	31	2	33
2024 May	24	3	27
2024 April	31	8	39
2024 March	39	11	50
2024 February	39	9	48
2024 January	40	7	47
2023 December	41	22	63
2023 November	38	6	44
2023 October	51	11	62
2023 September	39	7	46
2023 August	58	13	71
2023 July	25	5	30
2023 June	31	5	36
2023 May	52	8	60
2023 April	41	7	48
2023 March	20	8	28
2023 February	16	9	25
2023 January	18	13	31
2022 December	19	6	25
2022 November	31	8	39
2022 October	28	9	37
2022 September	30	23	53
2022 August	26	6	32
2022 July	23	15	38
2022 June	32	12	44
2022 May	24	10	34
2022 April	25	2	27
2022 March	24	8	32
2022 February	17	2	19
2022 January	14	6	20
2021 December	10	0	10
2021 November	11	2	13
2021 October	12	11	23

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter